The goal of this Phase 3 clinical trial is to test how safe and effective Belantamab Mafodotin is in the treatment of relapsed/refractory myeloma. One group of patients will receive Belantamab Mafodotin, and the other will receive Pomalidomide + low dose Dexamethasone. Researchers will compare the two groups of patients to help them understand how well Belantamab Mafodotin works when compared to Pomalidomide + Dexamethasone.
|Trial Phase||Phase 3|
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
Read the latest news and updates on this trial.
July 14, 2020
The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 12 to 0 in favor of approving belantamab mafodotin for the treatment of patients with relapsed/refractory multiple myeloma who have previously received at least 4 prior therapies, including an immunomodulatory drug, a proteasome inhibitor, and a CD38-directed antibody.
January 21, 2020
March 21, 2019
Median progression-free survival extends to twelve months
SparkCures is working closely with GlaxoSmithKline to provide the most up-to-date information on this clinical trial. Use the button above to add this trial to your list of favorites.
Learn more about how we work with trial sponsors